Synaptogenix Inc (SNPX)

[InTheTrenches]

Really good thoughts there, Coach.

You are right--without knowing the individual data, it's hard to determine why we didn't get 2-tailed statistical significance in the subgroup analysis. And, in the absence of that detailed information, the only thing that sticks out is that non-memantine placebo performed better than expected and better than overall placebo, and in a small sample size to boot (11 patients). Thanks for pointing that out.

What we all should hope for in the confirmatory phase 2 is that both Bryostatin and placebo groups perform as we expect. That is, we hope to see very few in the Bryostatin group that are non-performers, and we hope to see very few in the placebo group that see an improvement in MMSE score. This is what I'm really getting at with my previous posts today. I'd love to see "normal" data with very few outliers in the Bryostatin and placebo groups. If that is the case, we should pass with flying colors.

In the end, it comes down to trust, and I like that they've brought in stats experts to sign off on their trial design.